Meropenem Pristinamycin three dosage forms approved for new pediatric HSCT 200-day dosing regimen.

Merck announced that its new non-nucleoside cytomegalovirus inhibitor, Pradimycin three dosage forms - Letemovir tablets, Letemovir injection, and Letemovir tablets, have been approved by the China National Medical Products Administration for use in children aged 6 months and older weighing 6kg at risk of delayed CMV infection and CMV disease. Pradimycin can be used continuously for up to 200 days after HSCT.